GSK/Theravance Press Forward With Once-Daily LABA After FDA Vote On Asthma Class
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms await Phase IIb results for new inhaled corticosteroid to develop Phase III testing plan for potential successor to Advair.